ReviewNPJ vaccines2025
How Rwanda mounted a research response with an investigational vaccine just ten days into a Marburg outbreak.
Review in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Epidemiology and containment of the first Marburg virus disease outbreak in Ethiopia in 2025: A retrospective descriptive study.Global epidemiology · 2026Article
- Article
- Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections.EBioMedicine · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Crystal Structure of Měnglà Virus Nucleoprotein Bound by a Poorly Cross-Reactive Anti-Marburg Virus Nanobody Highlights a Single Amino Acid Affinity Switch, a Feature Also Evident in Dehong Virus.ACS infectious diseases · 2026Article
- Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases.BMJ medicine · 2026Review
- Strategies for Managing Marburg Virus Disease Outbreaks: Lessons from the Rwanda Outbreak.Infection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The September 2024 outbreak of Marburg virus disease (MVD) represented the first time this virus was identified in Rwanda. Health authorities mounted a rapid and effective response, including the rapid execution of an open-label Phase 2 clinical trial of an investigational Marburg vaccine, beginning just 10 days after the outbreak was declared. We share lessons from this rapidly executed clinical trial to help encourage outbreak research preparedness in other countries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.